JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.02B |
| 2 |
iShares US Treasury Bond ETF
GOVT
|
+$3.55B |
| 3 |
Eli Lilly
LLY
|
+$2.61B |
| 4 |
Amphenol
APH
|
+$2.33B |
| 5 |
TotalEnergies
TTE
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$9.67B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$7.48B |
| 3 |
Meta Platforms (Facebook)
META
|
+$7.25B |
| 4 |
NVIDIA
NVDA
|
+$6.05B |
| 5 |
Microsoft
MSFT
|
+$5.54B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.15% |
| 2 | Miscellaneous | 24.97% |
| 3 | Financials | 9.75% |
| 4 | Consumer Discretionary | 8.78% |
| 5 | Healthcare | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3326
iShares MSCI Germany ETF
EWG
$1.5B
| $4.31M | ﹤0.01% |
101,482
-2,091
| -2% | -$86.6K |
2013 Q2
50 quarters
|
|
3327
dLocal
DLO
$4.04B
| $4.31M | ﹤0.01% |
304,984
+31,584
| +12% | +$446K |
2022 Q1
15 quarters
|
|
|
OTF
3328
Blue Owl Technology Finance Corp
OTF
$4.39B
| $4.31M | ﹤0.01% |
296,205
+241,468
| +441% | +$3.39M |
2025 Q2
2 quarters
|
|
3329
Nu Skin
NUS
$224M
| $4.31M | ﹤0.01% |
447,624
-44,458
| -9% | -$460K |
2013 Q2
50 quarters
|
|
3330
Preferred Bank
PFBC
$1.26B
| $4.3M | ﹤0.01% |
45,528
+2,052
| +5% | +$191K |
2013 Q2
50 quarters
|
|
3331
CALL
SiteOne Landscape Supply
SITE
$3.91B
| $4.3M | ﹤0.01% |
+34,500
| New | +$4.37M |
2025 Q4
0 quarters
|
|
3332
Ardelyx
ARDX
$862M
| $4.29M | ﹤0.01% |
736,190
-267,099
| -27% | -$1.49M |
2017 Q3
33 quarters
|
|
3333
Principal Exchange-Traded Funds Principal US Mega-Cap ETF
USMC
$5.34B
| $4.29M | ﹤0.01% |
62,695
+14,470
| +30% | +$990K |
2023 Q4
8 quarters
|
|
3334
First Trust Short Duration Managed Municipal ETF
FSMB
$645M
| $4.29M | ﹤0.01% |
214,080
-29,026
| -12% | -$582K |
2022 Q4
12 quarters
|
|
3335
Erasca
ERAS
$5.16B
| $4.29M | ﹤0.01% |
1,153,090
-115,952
| -9% | -$326K |
2021 Q3
17 quarters
|
|
3336
National Healthcare
NHC
$3.57B
| $4.29M | ﹤0.01% |
31,289
-23,921
| -43% | -$3.09M |
2016 Q3
37 quarters
|
|
|
RERE
3337
ATRenew
RERE
$806M
| $4.29M | ﹤0.01% |
808,934
+436,577
| +117% | +$1.96M |
2023 Q2
10 quarters
|
|
3338
Invesco S&P 100 Equal Weight ETF
EQWL
$2.79B
| $4.28M | ﹤0.01% |
36,244
+108
| +0.3% | +$12.6K |
2024 Q2
6 quarters
|
|
3339
AAR Corp
AIR
$4.12B
| $4.28M | ﹤0.01% |
51,722
-39,798
| -43% | -$3.29M |
2013 Q2
50 quarters
|
|
3340
Brookfield Renewable
BEPC
$5.29B
| $4.28M | ﹤0.01% |
111,684
-117,204
| -51% | -$4.72M |
2020 Q3
21 quarters
|
|
3341
First Trust SMID Cap Rising Dividend Achievers ETF
SDVY
$11B
| $4.27M | ﹤0.01% |
111,464
+584
| +0.5% | +$22.2K |
2022 Q4
12 quarters
|
|
3342
Invesco Actively Managed Exch-Traded Commodity Fd Tr Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF
PDBC
$7.78B
| $4.27M | ﹤0.01% |
322,315
+113,311
| +54% | +$1.53M |
2021 Q1
19 quarters
|
|
3343
Dimensional Global Real Estate ETF
DFGR
$3.63B
| $4.26M | ﹤0.01% |
161,252
-21,755
| -12% | -$587K |
2023 Q1
11 quarters
|
|
3344
Taysha Gene Therapies
TSHA
$1.51B
| $4.26M | ﹤0.01% |
774,412
+478,168
| +161% | +$2.32M |
2020 Q4
20 quarters
|
|
|
ADAM
3345
Adamas Trust
ADAM
$702M
| $4.26M | ﹤0.01% |
583,267
-58,714
| -9% | -$417K |
2015 Q3
41 quarters
|
|
3346
PUT
Corning
GLW
$141B
| $4.26M | ﹤0.01% |
48,600
-14,100
| -22% | -$1.21M |
2021 Q3
17 quarters
|
|
3347
CALL
Neurocrine Biosciences
NBIX
$14.6B
| $4.25M | ﹤0.01% |
+30,000
| New | +$4.35M |
2025 Q4
0 quarters
|
|
|
3348
PUT
Neurocrine Biosciences
NBIX
$14.6B
| $4.25M | ﹤0.01% |
+30,000
| New | +$4.35M |
2025 Q4
0 quarters
|
|
3349
Coursera
COUR
$1.33B
| $4.25M | ﹤0.01% |
577,313
+359,010
| +164% | +$3.13M |
2021 Q1
19 quarters
|
|
3350
Amphastar Pharmaceuticals
AMPH
$1.08B
| $4.25M | ﹤0.01% |
158,644
-94,588
| -37% | -$2.44M |
2014 Q3
45 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2025 Portfolio in Review
As of Q4 2025, JP Morgan Chase held 7,944 positions worth $1.59T, down 4.6% from $1.67T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
JP Morgan Chase withdrew a net $106B in Q4 2025, closing 563 positions and reducing 3,329 holdings. Its most notable exit was Interpublic Group of Companies, an estimated $228M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, JP Morgan Chase opened a new position in Quadratic Interest Rate Volatility and Inflation Hedge ETF worth $99.9M.
- JP Morgan Chase's largest Q4 2025 buy was Quadratic Interest Rate Volatility and Inflation Hedge ETF: 5,216,227 shares worth $99.9M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q4 2025, an estimated $4.02B increase.
- JP Morgan Chase's biggest Q4 2025 reduction was Vanguard S&P 500 ETF, cutting an estimated $9.67B.
- JP Morgan Chase fully exited Interpublic Group of Companies in Q4 2025, selling an estimated $228M.
- JP Morgan Chase's ten largest holdings make up 26% of its $1.59T portfolio in Q4 2025.
- JP Morgan Chase opened 577 new positions and closed 563 in Q4 2025.
- JP Morgan Chase's portfolio value fell 4.6% quarter-over-quarter to $1.59T.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.